- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Colorectal cancer
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1818KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 674KB)
Pembrolizumab – March 2021
Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
2 July 2021